Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.

Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2016 Feb 9. [Epub ahead of print]

PMID:
26862949
2.

Developing in vitro models of human ductal carcinoma in situ from primary tissue explants.

Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, Brufsky AM, Johnson RR, Oesterreich S, McAuliffe PF.

Breast Cancer Res Treat. 2015 Sep;153(2):311-21. doi: 10.1007/s10549-015-3551-8. Epub 2015 Aug 18.

PMID:
26283301
3.

The molecular landscape of premenopausal breast cancer.

Liao S, Hartmaier RJ, McGuire KP, Puhalla SL, Luthra S, Chandran UR, Ma T, Bhargava R, Modugno F, Davidson NE, Benz S, Lee AV, Tseng GC, Oesterreich S.

Breast Cancer Res. 2015 Aug 7;17:104. doi: 10.1186/s13058-015-0618-8.

4.

Expression of high affinity folate receptor in breast cancer brain metastasis.

Leone JP, Bhargava R, Theisen BK, Hamilton RL, Lee AV, Brufsky AM.

Oncotarget. 2015 Oct 6;6(30):30327-33. doi: 10.18632/oncotarget.4639.

5.

BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.

Gau DM, Lesnock JL, Hood BL, Bhargava R, Sun M, Darcy K, Luthra S, Chandran U, Conrads TP, Edwards RP, Kelley JL, Krivak TC, Roy P.

Cell Cycle. 2015;14(12):1884-92. doi: 10.1080/15384101.2015.1036203.

PMID:
25927284
6.

The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation.

Wu Q, Madany P, Akech J, Dobson JR, Douthwright S, Browne G, Colby JL, Winter GE, Bradner JE, Pratap J, Sluder G, Bhargava R, Chiosea SI, van Wijnen AJ, Stein JL, Stein GS, Lian JB, Nickerson JA, Imbalzano AN.

J Cell Physiol. 2015 Nov;230(11):2683-94. doi: 10.1002/jcp.24991.

PMID:
25808524
7.

Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.

Li Z, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2015 Mar;143(3):451-8. doi: 10.1309/AJCPKIVVW4OBPX6I.

PMID:
25696805
8.

Primary and Radiation-induced Breast Angiosarcoma: Clinicopathologic Predictors of Outcomes and the Impact of Adjuvant Radiation Therapy.

Ghareeb ER, Bhargava R, Vargo JA, Florea AV, Beriwal S.

Am J Clin Oncol. 2014 Dec 17. [Epub ahead of print]

PMID:
25521258
9.

Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status.

Gloyeske NC, Woodard AH, Elishaev E, Yu J, Clark BZ, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):202-8. doi: 10.1097/PAI.0000000000000076.

PMID:
25356941
10.

A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages.

Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA, Weinberg RA.

Nat Cell Biol. 2014 Nov;16(11):1105-17. doi: 10.1038/ncb3041. Epub 2014 Sep 28.

11.

Clinical utility of immunohistochemistry and other ancillary techniques in assessment of uterine tumors.

Bhargava R.

Semin Diagn Pathol. 2014 May;31(3):193-4. doi: 10.1053/j.semdp.2014.03.001. Epub 2014 Apr 1. No abstract available.

PMID:
24933036
12.

Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.

Clark BZ, Beriwal S, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 Jul;142(1):64-71. doi: 10.1309/AJCP8H2VBDSCIOBF.

13.
14.

Low ER+ breast cancer: Is this a distinct group?

Gloyeske NC, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 May;141(5):697-701. doi: 10.1309/AJCP34CYSATWFDPQ.

15.

Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.

Gao FF, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2014 Jan;141(1):102-10. doi: 10.1309/AJCP6CXS8OSRHXIR.

16.

Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model.

Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA, Shiva SS, Bhargava R, Singh SV.

J Natl Cancer Inst. 2013 Aug 7;105(15):1111-22. doi: 10.1093/jnci/djt153. Epub 2013 Jul 2.

17.

Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis.

Ding Z, Joy M, Bhargava R, Gunsaulus M, Lakshman N, Miron-Mendoza M, Petroll M, Condeelis J, Wells A, Roy P.

Oncogene. 2014 Apr 17;33(16):2065-74. doi: 10.1038/onc.2013.166. Epub 2013 May 20.

18.

Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?

Gao FF, Bhargava R, Yang H, Li Z, Zhao C.

Hum Pathol. 2013 Aug;44(8):1534-43. doi: 10.1016/j.humpath.2012.12.007. Epub 2013 Mar 1.

PMID:
23465279
19.

Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.

Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R.

Int J Gynecol Cancer. 2013 Feb;23(2):380-4. doi: 10.1097/IGC.0b013e31825cc8ee.

PMID:
23318908
20.

Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

Li X, Kanbour-Shakir A, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):420-5. doi: 10.1097/PAI.0b013e318273c1cc.

PMID:
23165332
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk